Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: Effect of cyclosporin A

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 7, 2013, Pages 4717-4733

  Gao, Jianping ^a   Sana, Reuben ^a   Calder, Virginia ^b   Calonge, Margarita ^c   Lee, Wanju ^a   Wheeler, Larry A ^a   Stern, Michael E ^a  

^a ALLERGAN INC   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Apoptosis; Conjunctival epithelial cells; Cyclosporin A (CsA); Dry eye; Inflammation; Mitochondrial permeability transition pore (MPTP); T cells

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLOSPORIN A; CYTOCHROME C; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 2; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL DEATH; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CONJUNCTIVAL EPITHELIAL CELLS; CYCLOSPORIN A (CSA); DRY EYE; INFLAMMATION; MITOCHONDRIAL PERMEABILITY TRANSITION PORE (MPTP); T CELLS;

ANTIGENS, CD95; APOPTOSIS; CASPASES; CELL DEATH; CELLS, CULTURED; CONJUNCTIVA; CONJUNCTIVAL DISEASES; CYCLOSPORINE; EPITHELIAL CELLS; FAS LIGAND PROTEIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERFERON-GAMMA; JURKAT CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880318446     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11681     Document Type: Article

References (51)

1. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8:279-289.
2. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10:826-837.
3. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90-100.
4. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998; 17:584-589.
5. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409-416.
6. Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44:124-129.
7. Baudouin C, Liang H. Amplifying factors in ocular surface diseases: apoptosis. Ocul Surf. 2005;3(suppl 4):S194-S197.
8. Zhang X, Chen W, De Paiva CS, et al. Desiccating stress induces CD4{thorn} T-cell-mediated Sjögren's syndrome-like corneal epithelial apoptosis via activation of the extrinsic apoptotic pathway by interferon-c. Am J Pathol. 2011;179:1807-1814.
9. Gao J, Schwalb TA, Addeo JV, Ghosn CR, Stern ME. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea. 1998;17:654-663.
10. Zhou Y, Wang CF, Jiang T. Expression of apoptosis related genes and changes of lacrimal functions in main lacrimal gland extirpation xerophthalmia model. Zhonghua Yan Ke Za Zhi. 2007;43:18-22.
11. Bulosan M, Pauley KM, Yo K, et al. Inflammatory caspases are critical for enhanced cell death in the target tissue of Sjögren's syndrome before disease onset. Immunol Cell Biol. 2009;87: 81-90.
12. Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005;24:80-85.
13. De Saint Jean M, Debbasch C, Rahmani M, et al. Fas- and interferon c-induced apoptosis in Chang conjunctival cells: further investigations. Invest Ophthalmol Vis Sci. 2000;41: 2531-2543.
14. Zhang X, Chen W, De Paiva CS, et al. Interferon-c exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Invest Ophthalmol Vis Sci. 2011;52: 6279-6285.
15. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626-629.
16. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87:99-163.
17. Giorgio V, Soriano ME, Basso E, et al. Cyclophilin D in mitochondrial pathophysiology. Biochim Biophys Acta. 2010; 1797:1113-1118.
18. Ridder WH III. Cyclosporin use in dry eye disease patients. Expert Opin Pharmacother. 2008;9:3121-3128.
19. Foulks GN. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin. 2006;46:105-122.
20. Sun J, Wang J. Cyclosporine inhibits apoptosis in experimental murine xerophthalamia conjunctival epithelium. J Huazhong Univ Sci Technolog Med Sci. 2006;26:469-471.
21. Brignole F, Pisella PJ, De Saint Jean M, Goldschild M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci. 2001;42:90-95.
22. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107:631-639.
23. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609-2614.
24. Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci. 2000;41:1356-1363.
25. Gürdal C, Genç I, Saraç O, Gönül I, Takmaz T, Can I. Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression. Curr Eye Res. 2010;35:771-777.
26. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136-142.
27. Marienfeld R, Neumann M, Chuvpilo S, et al. Cyclosporin A interferes with the inducible degradation of NF-kB inhibitors, but not with the processing of p105/NF-kB1 in T cells. Eur J Immunol. 1997;27:1601-1609.
28. Du S, Hiramatsu N, Hayakawa K, et al. Suppression of NFkappaB by cyclosporin A and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response. J Immunol. 2009;182:7201-7211.
29. Connern CP, Halestrap AP. Recruitment of mitochondrial cyclophilin to the mitochondrial inner membrane under conditions of oxidative stress that enhance the opening of calcium-sensitive non-specific channel. Biochem J. 1994;302: 321-324.
30. Fournier N, Ducet G, Crevat A. Action of cyclosporine on mitochondrial calcium fluxes. J Bioenerg Biomembr. 1987;19: 297-303.
31. Argaud L, Gateau-Roesch O, Muntean D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol. 2005;38: 367-374.
32. Javadov S, Karmazyn M, Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther. 2009;330: 670-678.
33. Debbasch C, Pisella PJ, De Saint Jean M, Rat P, Warnet JM, Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved betablockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001;42:2525-2533.
34. Diebold Y, Calonge M, Enríquez de Salamanca A, et al. Characterization of a spontaneously immortalized cell line (IOBA-NHC) from normal human conjunctiva. Invest Ophthalmol Vis Sci. 2003;44:4263-4274.
35. Enríquez-de-Salamanca A, Calder V, Gao J, et al. Cytokine responses by conjunctival epithelial cells: an in vitro model of ocular inflammation. Cytokine. 2008;44:160-167.
36. Basso E, Petronili V, Forte MA, Bernardi P. Phosphate is essential for inhibition of the mitochondrial permeability transition pore by cyclosporin A and by cyclophilin D ablation. J Biol Chem. 2008;283:26307-26311.
37. Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA. Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. BioTechniques. 2011;50:98-115.
38. Crispe IN. Fatal interactions: Fas-induced apoptosis of mature T cells. Immunity. 1994;1:347-349.
39. Klas C, Debatin KM, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol. 1993;5:625-630.
40. Zhu JY, Giaisi M, Köhler R, et al. Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ. 2009;16:1289-1299.
41. Mukerjee N, McGinnis KM, Gnegy ME, Wang KK. Caspasemediated calcineurin activation contributes to IL-2 release during T cell activation. Biochem Biophys Res Commun. 2001;285:1192-1199.
42. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41-101.
43. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25: 4798-4811.
44. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647-656.
45. Chan CC, Matteson DM, Li Q, Whitcup SM, Nussenblatt RB. Apoptosis in patients with posterior uveitis. Arch Ophthalmol. 1997;115:1559-1567.
46. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev. 2003;193:70-81.
47. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128: 255-266.
48. Mingullon J, Morancho B, Kim S-J, Lopez-Botet M, Aramburu J. Concentration of cyclosporin A and FK506 that inhibit IL-2 in human T cells do not affect TGF-b1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-b1. J Leukoc Biol. 2005;77:748-758.
49. Matsuda S, Shibasaki F, Takehana K, Mori H, Nishida E, Koyasu S. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep. 2000;1:428-434.
50. Green DR. Death and NFjB in T cell activation: life at the edge. Mol Cell. 2003;11:551-552.
51. Campello S, Scorrano L. Mitochondrial shape changes: orchestrating cell pathophysiology. EMBO Rep. 2010;11:678-684.